Reported research findings
- No established human clinical trials define efficacy or safety in people to date.
WEIGHT & METABOLIC RESEARCH
SLU-PP-332
Studied in models as an “exercise mimetic”—a compound that switches on some of the same pathways as endurance training.
SLU-PP-332 activates the estrogen-related receptors (ERR), a family of switches that control how cells produce and spend energy. Often called an exercise mimetic, it turns on metabolic pathways normally associated with endurance training—building more mitochondria, burning more fat, and raising energy expenditure—in preclinical models. Evidence to date is preclinical, with no established human trials.
Why BLP features SLU-PP-332
Included as an early-stage research compound with a specific ERR-receptor mechanism and interesting exercise-mimetic modeling. Evidence is preclinical and its real-world use history is minimal, so it is clearly presented as experimental.
Mechanism
Potently activates all three estrogen-related receptors, switching on the same gene programs that aerobic exercise turns on.
Increases the number and capacity of mitochondria—the cell's energy factories—in skeletal-muscle models.
Shifts muscle fibers toward the fat-burning type and increases fat oxidation, without any change in food intake or activity level.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- In obese models: reduced fat-mass accumulation and progressive body-fat loss with no change in appetite.
- Reported increased endurance capacity and mitochondrial efficiency.
- Reported better body composition with preserved muscle in models.
- Preclinical animal studies reported a favorable short-term safety profile at research doses; reported effects can include increased warmth or sweating from elevated metabolism.
Regulatory status
SLU-PP-332 is investigational with preclinical evidence only and no established human trials. Sold and offered strictly for laboratory and research use.